Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Value of the Serum Thyroglobulin Level Alteration at the First High Dose Radioiodine Treatment in Patients with Differentiated Thyroid Carcinoma

분화성갑상선암에서 최초 고용량 방사성요오드 치료시 혈청 갑상선글로불린 수치 변화의 의의

  • Nam, Hyun-Yeol (Department of Nuclear Medicine, Pusan National University Hospital) ;
  • Kim, In-Joo (Department of Nuclear Medicine, Pusan National University Hospital) ;
  • Kim, Yong-Ki (Department of Nuclear Medicine, Pusan National University Hospital) ;
  • Kim, Seong-Jang (Department of Nuclear Medicine, Pusan National University Hospital) ;
  • Jun, Sung-Min (Department of Nuclear Medicine, Pusan National University Hospital) ;
  • Kim, Bum-Soo (Department of Nuclear Medicine, Pusan National University Hospital)
  • 남현열 (부산대학교 병원 핵의학과) ;
  • 김인주 (부산대학교 병원 핵의학과) ;
  • 김용기 (부산대학교 병원 핵의학과) ;
  • 김성장 (부산대학교 병원 핵의학과) ;
  • 전성민 (부산대학교 병원 핵의학과) ;
  • 김범수 (부산대학교 병원 핵의학과)
  • Published : 2009.08.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The purpose of this study was to evaluate if short-term serum thyroglobulin (Tg) elevation after radioiodine administration can predict successful radioiodine remnant ablation (RRA) and whether comparable RRA effectiveness is exhibited between a group administered with recombinant human thyrotropin (rhTSH) and a group experiencing thyroid hormone withdrawal (THW), in preparation for RRA. Materials and Methods: A retrospective chart review was performed on 39 patients in the rhTSH group and 46 patients in the THW group. They were treated for differentiated thyroid carcinoma by total or near total thyroidectomy, and referred for RRA between 2003 and 2006 (the rhTSH group) and between January and June of 2006 (the THW group). They were assessed for serum Tg levels just before I-131 administration (TgD0), reassessed 9 days later (TgD9), and again 6-12 months later. Results: RRA was successful in 64 (37 from the THW group and 27 from the rhTSH group) of the total 85 patients. The success rates of RRA had no statistically significant differences between the two groups. In both groups, TgD9/TgD0 values were significantly higher in the RRA success group (the rhTSH group; P = 0.03, the THW group; P = 0.04). By combining cutoff values of TgD0 and TgD9/TgD0, the successful RRA value was determined to be 96.7% (29/30) with TgD0$\leq$5.28 ng/mL and TgD9/TgD0>4.37 in both groups (the rhTSH group; 100% (16/16), the THW group; 92.9% (13/14)). Using logistic multivariate analysis, only TgD0 was independently associated with successful RRA. Conclusion: We may predict successful ablation by evaluating short-term serum Tg elevation after I-131 administration for RRA, in both rhTSH and THW patients.

목적: 이 연구에서는 고용량 방사성요오드 치료 시행 전, 각각 rhTSH 전처치를 시행한 환자군(rHTSH군)과 갑상선 호르몬 투여 중단 시행한 환자군(THW군)에서 방사성요오드 투여 후 단기 혈청 갑상선글로불린(Tg) 상승 정도가 성공적인 잔여갑상선 제거(RRA)를 예측할 수 있는지, 그리고 두 군 사이에서 동등한 잔여갑상선 제거 효과를 보이는지 알아보았다. 대상 및 방법: 분화성갑상선암으로 수술후 방사성요오드 치료를 받은 환자들 중, rhTSH군은 2003년 1월에서 2006년 12월까지 39명, THW군은 2005년 1월에서 2005년 6월까지 46명을 대상으로 후향적으로 평가하였다. 이들은 방사성요오드 투여하는 날, 방사성요오드 투여 후 9일째 되는 날 및 6개월에서 12개월 사이에 시행한 추적 검사에서 갑상선기능검사를 시행하였다. 결과: 85명 중 64명에서 성공적 인 RRA를 보였다. rhTSH 군에서는 27명, THW 군에서는 37명에서 RRA 성공을 보였고 이 두 군의 결과는 유의한 차이를 보이지 않았다(p=0.347). rhTSH군 및 THW군에서 TgD9/TgD0은 RRA 성 공군에서 실패군보다 유의하게 높은 값을 보였다(p=0.03, p=0.04) TgD0와 TgD9/TgD0의 절단값을 결합하였을 경우, TgD0가 5.28 이하이면서 TgD9/TgD0이 4.37초과인 경우 96.7%(29/30)의 RRA 성공률을 보였고, rhTSH군과 THW군에서도 각각 92.9%(13/14)와 100%(16/16)의 높은 HRA 성공률을 나타냈다. 로지스틱 회귀분석에서는 오직 TgD0만 성공적인 RRA와 유의한 연관성을 보였다(p=0.001). 결론: THW군뿐 아니라 rhTSH군에서도 RRA를 위한 고용량 방사성요오드 치료 도중의 혈청 갑상선글로불린의 변화 양상으로 향후 성공적인 RRA를 예측할 수 있다.

Keywords

References

  1. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999;9:421-7 https://doi.org/10.1089/thy.1999.9.421
  2. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy tor papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-63 https://doi.org/10.1210/jc.86.4.1447
  3. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oven WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008;35:1941-59 https://doi.org/10.1007/s00259-008-0883-1
  4. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein He. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3668-76 https://doi.org/10.1210/jc.2003-031167
  5. Schlumberger M, Pacini F, Wiersinga WM, Toft A, Smit JW, Sanchez Franco F, et al. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol 2004;151:539-48 https://doi.org/10.1530/eje.0.1510539
  6. Sweeney DC, Johnston GS. Radioiodine therapy tor thyroid cancer. Endocrinol Metab Clin North Am 1995;24:803-39
  7. Dow KH, Ferrell BR, Anello C. Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997;7:613-9 https://doi.org/10.1089/thy.1997.7.613
  8. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006;91:878-84 https://doi.org/10.1210/jc.2005-2064
  9. Crevenna R, Zettinig G, Keilani M, Posch M, Schmidinger M, Pirich C, et al. Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxin supplementation therapy. Support Cancer Care 2003;11:597-603 https://doi.org/10.1007/s00520-003-0474-4
  10. Botella-Carretero JI, Galan JM, Caballero C, Sancho J, Escobar-Morreale HF. Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 2003;10:601-10 https://doi.org/10.1677/erc.0.0100601
  11. Sugino K, Ito K, Takami H. Management of differentiated thyroid carcinoma with radioiodine and recombinant human TSH. Endocr J 2006;53:723-8 https://doi.org/10.1507/endocrj.KR-88
  12. Robbins RJ, Robbins AK. Clinical review 156: recombinant human thyrotropin and thyroid cancer management. J Clin Endocrinol Metab 2003;88:1933-8 https://doi.org/10.1210/jc.2002-021979
  13. Pacini F. Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91:926-32 https://doi.org/10.1210/jc.2005-1651
  14. Torrens J, Burch HB. Serum thyroglobulin measurement: Utility in clinical practice. Endocrinol Metab Clin North Am 2001;30:1-34 https://doi.org/10.1016/S0889-8529(08)70016-1
  15. Bernier MO, Morel O, Rodien P, Muratet JP, Giraud P, Rohmer V, et al. Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer. Eur J Nucl Med Imaging 2005;32:1418-21 https://doi.org/10.1007/s00259-005-1866-0
  16. Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, et al. Recombinant-human TSH-assisted radioactive iodine remnant ablation achieves short term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008;49:764-70 https://doi.org/10.2967/jnumed.107.049072
  17. Lee HJ, Rha SY, Jo YS, Kim SM, Ku BJ, Shong M, et al. Predictive value of the preablation serum thyroglobulin level after thyroidectomy is combined with postablation $^{131}$I whole body scintigraphy for successful ablation in patients with differentiated thyroid carcinoma. Am J Clin Oncol 2007;30:63-8 https://doi.org/10.1097/01.coc.0000239138.64949.0a
  18. Arslan N, Ilgan S, Serdengecti M, Ozguven MA, Bayhan H, Okuyucu K, et al. Post-surgical ablation of thyroid remnants with high-dose $^{131}$I in patients with differentiated thyroid carcinoma. Nucl Med Commun 2001;22:1021-7 https://doi.org/10.1097/00006231-200109000-00012
  19. Karam M, Gianoukakis A, Feustel PJ, Cheema A, Postal ES, Cooper JA. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Nucl Med Commun 2003;24:489-95 https://doi.org/10.1097/00006231-200305000-00002
  20. Menzel C, Kranert WT, Dobert N, Diehl M, Fietz T, Harnscho N, et al. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of $^{131}$I. J Nucl Med 2003;44:1065-8
  21. Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, Berriolo A, et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after $^131}$I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 2004;45:988-94
  22. Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 1999;26:1448-52 https://doi.org/10.1007/s002590050477
  23. Lima N, Cavaliere H, Tomimori E, Knobel M, Medeiros-Neto G. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer. J Endocrinol Invest 2002;25:110-5 https://doi.org/10.1007/BF03343973
  24. Cramp WA, Yatvin MB, Harms-Ringdahl M. Recent developments in the radiobiology of cellular membranes. Acta Oncol 1994;33:945-52 https://doi.org/10.3109/02841869409098462
  25. Rosario PW, Purisch S. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 <1 ng/ml determined by traditional assays? Clin Endocrinol (Oxf) 2008;68:338-42 https://doi.org/10.1111/j.1365-2265.2007.03043.x
  26. Giovanella L, Ceriani L, Ghelfo A, Keller F, Sacchi A, Maffioli M, et at. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures. Clin Chem Lab Med 2006;44:648-52 https://doi.org/10.1515/CCLM.2006.107